Frontlight ResearchEarly access
Taking people in United StatesPhase 3
Berobenatide for knee pain in adults with overweight or obesity
Tests berobenatide against placebo in adults with knee osteoarthritis and excess weight.
Key facts
- Who runs it
- Pfizer
- Where
- Albuquerque, Charlottesville, Chicago, Clearwater, Colorado Springs, Dallas, Doral, Duncansville, Escondido, Farmington Hills, Fort Worth, Granite Quarry, Gretna, Houston, Jacksonville, Kingwood, Lady Lake, Monroe, Norman, Ocala, Rancho Cucamonga, Salisbury, Shavano Park, Sterling Heights, Stockbridge, Tampa, Tempe, Tomball, Tustin, Waco, Wichita, Wilmington, and Woodstock, United StatesSee the 39 sitesAlso in 2 other countries, 9 sites
- Trial code
- Registry title
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 656 people, planned
- Started
- 26 Oct 2026
- Expected to end
- 10 Oct 2028
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Berobenatide
- Placebo
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with painful knee osteoarthritis who are also overweight or obese. It lasts 52 weeks and compares monthly berobenatide injections with placebo.
- Age
- 18 years or older, or the minimum age of consent set by local rules.
- Sex
- All sexes can join.
- Disease stage
- Knee osteoarthritis meeting American College of Rheumatology criteria, with knee pain and a knee X-ray showing Kellgren-Lawrence Grade 2 or 3.
- Earlier treatment
- At least 1 self-reported unsuccessful diet attempt to lose weight. People must be willing to stop pain medicines for a washout period. Recent weight-loss medicines, glucose-lowering treatments or other banned treatments are not allowed.
- Biomarker or test result
- Body mass index of at least 27 kg/m² at Screening.
Main reasons for not taking part
- History of diabetes or screening blood tests pointing to diabetes
- Body weight change of more than 5% in the 90 days before Screening
- Pancreatitis, gallbladder disease with symptoms, or a known stomach-emptying problem
- Personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- Earlier knee replacement, or planned knee replacement or knee surgery in the target knee
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adults 18 years of age or older, or the minimum age of consent according to local regulations
- Body mass index of at least 27 kg/m² at Screening
- Currently meets American College of Rheumatology (ACR) Criteria for knee OA
- Pain due to knee OA
- Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3
- Willingness to complete the required analgesic washout
- History of at least 1 self-reported unsuccessful dietary effort to lose body weight
Who cannot take part
- Self-reported body weight increase or decrease greater than 5% within 90 days before Screening
- Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study
- Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo
- Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease
- Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- Significant active or unstable psychiatric disorder
- Condition or knee disorder that could confound assessment of target-knee pain
- Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient
- History of diabetes or Screening laboratory findings indicative of diabetes
- Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment
Where in United States
Also in 2 other countries, 9 sites
- Albuquerque Clinical Trials, Inc.Albuquerque, United StatesNot yet recruiting
- Charlottesville Medical Research Center, LLCCharlottesville, United StatesNot yet recruiting
- Great Lakes Clinical Trials LLC dba Flourish ResearchChicago, United StatesNot yet recruiting
- Northwestern MedicineChicago, United StatesNot yet recruiting
- Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG)Chicago, United StatesNot yet recruiting
- Northwestern Memorial Hospital, Investigational Drug ServiceChicago, United StatesNot yet recruiting
- Northwestern University Feinberg School of MedicineChicago, United StatesNot yet recruiting
- Clinical Research of West Florida, Inc.Clearwater, United StatesNot yet recruiting
- Skylight Health ResearchColorado Springs, United StatesNot yet recruiting
- Mercy Family ClinicDallas, United StatesNot yet recruiting
- Universal Axon Clinical Research LLCDoral, United StatesTaking people
- Altoona Center For Clinical ResearchDuncansville, United StatesTaking people
- Headlands Research California, LLCEscondido, United StatesNot yet recruiting
- Profound Research, LLCFarmington Hills, United StatesTaking people
- Cedar Health ResearchFort Worth, United StatesNot yet recruiting
- Novant Health Granite Quarry Internal Medicine (knee x-ray)Granite Quarry, United StatesNot yet recruiting
- BRCR Global LouisianaGretna, United StatesNot yet recruiting
- JCCT- Juno NW HoustonHouston, United StatesNot yet recruiting
- Westside Center for Clinical ResearchJacksonville, United StatesNot yet recruiting
- Activian Clinical ResearchKingwood, United StatesNot yet recruiting
- Renstar Medical ResearchLady Lake, United StatesNot yet recruiting
- Monroe Biomedical ResearchMonroe, United StatesTaking people
- AMR ClinicalNorman, United StatesNot yet recruiting
- Renstar Medical ResearchOcala, United StatesNot yet recruiting
- Prospective Research Innovations IncRancho Cucamonga, United StatesNot yet recruiting
- Accellacare - SalisburySalisbury, United StatesNot yet recruiting
- Consano Clinical Research, LLCShavano Park, United StatesNot yet recruiting
- Revive Research Institute, Inc.Sterling Heights, United StatesTaking people
- Clinical Research AtlantaStockbridge, United StatesNot yet recruiting
- Clinical Research of West Florida IncTampa, United StatesNot yet recruiting
- AMR ClinicalTempe, United StatesNot yet recruiting
- DM Clinical ResearchTomball, United StatesNot yet recruiting
- Solace Clinical ResearchTustin, United StatesNot yet recruiting
- Velocity Clinical Research, WacoWaco, United StatesNot yet recruiting
- Elevate Clinical ResearchWichita, United StatesNot yet recruiting
- AccellacareWilmington, United StatesTaking people
- Delaney RadiologistWilmington, United StatesTaking people
- North Georgia Clinical Research, LLCWoodstock, United StatesNot yet recruiting
- North Georgia Internal MedicineWoodstock, United StatesNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
The 4 groups in the trial
- PlaceboPlacebo, for comparison
Participants will receive placebo as subcutaneous injection
- Arm 1: Berobenatide Once MonthlyTreatment being tested
Participants will receive berobenatide by subcutaneous injection.
Treatment: Berobenatide
- Arm 2: Berobenatide Once MonthlyTreatment being tested
Participants receive berobenatide by subcutaneous injection.
Treatment: Berobenatide
- Arm 3: Berobenatide Once MonthlyTreatment being tested
Participants receive berobenatide by subcutaneous injection.
Treatment: Berobenatide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)
- Plain-language title
- Berobenatide for knee pain in adults with overweight or obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Record updated
- 5 November 2026